StoneX Group’s 4D Molecular Therapeutics FDMT Stock Holding History

StoneX Group’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$161K	Buy	+12,469	New	+$162K	0.01%	1418

Other funds holding FDMT

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $109B AUM 51.53% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Perigon Wealth Management San Francisco, California $6.5B AUM 20.72% 1-Year Est. Return

Hussman Strategic Advisors Ellicott City, Maryland $469M AUM 10.16% 1-Year Est. Return

StoneX Group's FDMT Position: Q3 2026 in Review

StoneX Group opened a new position in 4D Molecular Therapeutics (FDMT) in Q3 2026: 12,469 shares worth $161K. The stake represents 0.01% of the portfolio and ranks #1418 among its holdings.

61 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.

StoneX Group held 12,469 shares of 4D Molecular Therapeutics worth $161K as of Q3 2026.
4D Molecular Therapeutics was a new StoneX Group position in Q3 2026.
4D Molecular Therapeutics made up 0.01% of StoneX Group's portfolio in Q3 2026, its #1418 holding.
61 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.

Based on StoneX Group's 13F filing for Q3 2026, filed 3 Nov 2026.